Skip to main content
SpringerLink
Log in

Vascular risk factors don't impact safety of apixaban

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Lopes RD, Al-Khatib SM, Wallentin L, Yang H, Ansell J, et al. Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial. Lancet: [10 pages], 2 Oct 2012. Available from: URL: http://dx.doi.org/10.1016/S0140-6736(12)60986-6

  2. Vassiliou VS, Flynn PD.Apixaban in atrial fi brillation: does predicted risk matter? Lancet: 2 Oct 2012. Available from: URL: http://dx.doi.org/10.1016/S0140-6736(12)61673-0

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vascular risk factors don't impact safety of apixaban. React. Wkly. 1423, 4 (2012). https://doi.org/10.2165/00128415-201214230-00010

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-201214230-00010

Keywords

Search

Navigation